Medullary thyroid cancer in a patient with hirschsprung disease with a C609Y germline RET-mutation

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 2, 2005, Pages 226-229

  De Groot, Jan Willem B ^a   Sijmons, Rolf H ^a   Links, Thera P ^a   Plukker, John Th M ^a   Hofstra, Robert M W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CASE REPORT; FEMALE; GENE MUTATION; GENETIC SCREENING; HIRSCHSPRUNG DISEASE; HUMAN; LYMPH NODE DISSECTION; ONCOGENE RET; PRIORITY JOURNAL; PROTO ONCOGENE; PULL THROUGH OPERATION; RECTUM RESECTION; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADULT; CARCINOMA, MEDULLARY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HIRSCHSPRUNG DISEASE; HUMANS; PEDIGREE; THYROID NEOPLASMS;

EID: 13944283389     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200502000-00028     Document Type: Article

References (27)

1. Dehner LP. Pediatric Surgical Pathology. Baltimore: Williams & Wilkins, 1987:394-7.
2. Badner JA, Sieber WK, Garver KL, Chakravarti A. A genetic study of Hirschsprung disease. Am J Hum Genet 1990;46:568-80.
3. Angrist M, Bolk S, Thiel B, et al. Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. Hum Mol Genet 1995;4:821-30.
4. Sijmons RH, Hofstra RMW, Wijburg FA, et al. Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 1998;43:542-7.
5. Hofstra RMW, Wu Y, Stulp RP, et al. RET and GDNF gene scanning in Hirschsprung patients using two dual denaturing gel systems. Hum Mutat 2000;15:418-29.
6. Mulligan LM, Eng C, Attié T, et al. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum Mol Genet 1994;3:2163-7.
7. Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Hum Mol Genet 1998;7:129-34.
8. Nishikawa M, Murakumo Y, Imai T, et al. Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. Eur J Hum Genet 2003;11:364-8.
9. Caron P, Attié T, David D, et al. C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Clin Endocrinol Metab 1996;81:2731-3.
10. Peretz H, Luboshitsky R, Baron E, et al. Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting. Hum Mutat 1997;10:155-9.
11. Pasini B, Rossi R, Ambrosio MR, et al. RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 2002;131:373-81.
12. Borst MJ, VanCamp JM, Peacock ML, Decker RA. Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 1995;117:386-91.
13. Decker RA. Long-term follow-up of a large North American kindred with multiple endocrine neoplasia type 2a. Surgery 1992;112:1066-72.
14. Romeo G, Ceccherini I, Celli J, et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med 1998;243:515-20.
15. Blank RD, Sklar CA, Dimich AB, LaQuaglia MP, Brennan MF. Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds. Cancer 1996;78:1996-2003.
16. Sen M, Yin L, Barone V, et al. Frequency of RET mutations in long- and short-segment Hirschsprung disease. Hum Mutat 1997;9:243-9.
17. Borrego S, Eng C, Sanchez B, Saez ME, Navarro E, Antinolo G. Molecular analysis of the RETt and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease. J Clin Endocrinol Metab 1998;83:3361-4.
18. Inoue K, Shimotake T, Inoue K, Tokiwa K, Iwai N. Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. J Pediatr Surg 1999;34:1552-4.
19. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
20. Pasini B, Borrello MG, Greco A, et al. Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet 1995;10:35-40.
21. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 1996;276:1575-9.
22. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995;267:381-3.
23. Heshmati HM, Gharib H, Khosla S, Abu-Lebdeh HS, Lindor NM, Thibodeau SN. Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. Mayo Clin Proc 1997;72:430-6.
24. Szinnai G, Meier C, Komminoth P, Zumsteg UW. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Pediatrics 2003;111:E132-9.
25. Gagel RF, Tashjian AH Jr, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988;318:478-84.
26. Kahraman T, de Groot JWB, Rouwe C, et al. Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. Eur J Surg Oncol 2003;29:331-5.
27. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 2003;349:1517-25.